RxDoctor Payments DataLook up a doctor →

Sumant Lamba, MD

Interventional Cardiology · Jacksonville, FLNPI 1306804687

Payments from drug & device makers

$861,644in general payments, 2019–2025

Across 637 payments — averaging $1352.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$409K
  • Amgen$130K
  • Abbott$89K
  • Boehringer Ingelheim International GmbH$62K
  • Medtronic$55K
  • Cvrx, Inc.$47K
  • plus $70K from 50 others

What the payments were for

  • Consulting fees$7,72831%
  • Travel & lodging$1,4576%
  • Food & beverage$15,93963%
  • Education$1090%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.52$409,325
Amgen61$129,720
Abbott54$88,651
Boehringer Ingelheim International GmbH61$62,083
Medtronic(2 entities)38$55,165
Cvrx, Inc.45$46,968
Boehringer Ingelheim Pharma GmbH & Co.kg7$26,494
Astrazeneca UK Limited2$16,517
Boston Scientific12$12,235
Abiomed51$4,547
Vifor (international) Ltd.1$3,000
Cardiovascular Systems Inc.7$1,033
Actelion Pharmaceuticals US, Inc.42$938
Boehringer Ingelheim27$440
AstraZeneca17$428
Novartis20$384
Merck10$346
Johnson & Johnson14$283
Pfizer13$270
Inari Medical, Inc.3$253
ZOLL Circulation Inc3$195
Acist Medical Systems, Inc.9$189
Inspire Medical Systems, Inc.2$152
Siemens Medical Solutions USA, Inc.3$149
Bayer9$146
Shockwave Medical, Inc2$143
Impulse Dynamics (USA) Inc.6$138
Sanofi-aventis U.S. LLC6$127
Avantec Vascular Corporation1$117
Edwards Lifesciences1$99
United Therapeutics Corporation4$95
Philips North America LLC2$90
Penumbra, Inc.7$88
E.r. Squibb & Sons, L.L.C.5$88
Innovation Technologies Inc2$74
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$65
Daiichi Sankyo Inc.3$55
Chiesi USA, Inc.3$41
Biotronik Inc.2$41
Alnylam Pharmaceuticals Inc.2$38
Kestra Medical Technology Services, Inc.2$37
Lexicon Pharmaceuticals, Inc.2$37
GSK2$37
Esperion Therapeutics, Inc.2$36
Novo Nordisk2$35
Irhythm Technologies, Inc.2$34
Baxter Healthcare2$30
Kiniksa Pharmaceuticals, Ltd.2$30
Kiniksa Pharmaceuticals International, PLC1$25
Atricure, Inc.1$25
Bardy Diagnostics, Inc.2$24
Gilead1$19
Arbor Pharmaceuticals, Inc.1$17
Astellas Pharma US Inc1$17
Regeneron Healthcare Solutions, Inc.1$15
Scpharmaceuticals Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$861,644 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$279,276
Medicare patients
917
Services billed
2,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan211$298,696
EliquisApixaban242$247,602
FarxigaDapagliflozin Propanediol183$215,660
JardianceEmpagliflozin141$195,629
XareltoRivaroxaban40$63,566
Repatha SureclickEvolocumab16$16,195
CorlanorIvabradine Hcl20$15,668
Repatha PushtronexEvolocumab11$6,937
Ranolazine ErRanolazine38$6,666
Metoprolol Succinate479$5,826
Losartan Potassium415$3,534
ClopidogrelClopidogrel Bisulfate303$2,856
Atorvastatin Calcium340$2,547
Rosuvastatin Calcium261$2,531
Prasugrel Hcl28$2,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$384$298,696211 claims
PfizerEliquis$270$247,602242 claims
AstraZenecaFarxiga$428$215,660183 claims
Boehringer IngelheimJardiance$440$195,629141 claims
Johnson & JohnsonXarelto$283$63,56640 claims
AmgenCorlanor$129,720$15,66820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →